RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial

PURPOSE: Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Radiat Oncol
Main Authors: Martin, Daniel, Balermpas, Panagiotis, Gollrad, Johannes, Weiß, Christian, Valentini, Chiara, Stuschke, Martin, Schäfer, Henning, Henkenberens, Christoph, Debus, Jürgen, Krug, David, Kuhnt, Thomas, Brunner, Thomas, Bostel, Tilman, Engenhart-Cabillic, Rita, Nestle, Ursula, Combs, Stephanie E., Belka, Claus, Hautmann, Matthias, Hildebrandt, Guido, Gani, Cihan, Polat, Bülent, Rödel, Claus, Fokas, Emmanouil
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7218223/
https://ncbi.nlm.nih.gov/pubmed/32420463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2020.04.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados